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residual varicosities, if required, was more cost-
effective and resulted in greater improvement in 
quality of life than the use of foam sclerotherapy 
alone.
The trial also showed that the majority of 
patients who underwent endothermal ablation 
did not require additional treatment for residual 
varicosities. This indicates that combinations of 
less invasive therapies are not always required to 
achieve the best result for the individual patient.
The trial did not set out to look at the effect of 
endothermal ablation alone, since this policy may 
lead to undertreatment of patients and prevent 
them from obtaining the best result. Thus, we 
do not consider that Jindeel’s proposed post hoc 
analysis to determine the effect of laser therapy 
alone would help to direct clinical practice.
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Magnetic Resonance Perfusion or Fractional Flow Reserve  
in Coronary Disease
To the Editor: A key assumption in the physio-
logical assessment of coronary stenosis in the 
MR-INFORM (Myocardial Perfusion CMR versus 
Angiography and FFR to Guide the Management 
of Patients with Stable Coronary Artery Disease) 
trial by Nagel et al. (June 20 issue)1 is that the two 
catheter systems used to measure the pressure 
gradient across a coronary stenosis are identical 
with respect to calibration and zero level. The 
article and Supplementary Appendix (available 
with the full text of the article at NEJM.org) do 
not provide this assurance.
The pressure gradient was measured between 
the catheter, which was positioned in the ascend-
ing aorta or coronary artery proximal to the 
stenosis, and the micromanometer at the tip of 
the guidewire, which had been advanced beyond 
the stenosis. The measuring sites could have 
been at different hydrostatic levels, and 10 mm Hg 
could have added to or subtracted from the gra-
dient if positioned 13 cm above or below the 
reference level.2 Such a problem, and discordant 
results, are discussed in an editorial by Alfonso 
and Rivero3 — the same stenosis had a fractional 
flow reserve (FFR) of 0.72 (warranting percuta-
neous coronary intervention [PCI]) and an instan-
taneous wave-free ratio of 0.92 (not warranting 
PCI). Could more information on this issue be 
provided by switching manometers to the two 
sensors or by using the same manometric sys-
tem at both sites?
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To the Editor: In the United States, approxi-
mately 300,000 patients with stable coronary ar-
tery disease undergo PCI annually.1 Cardiologists 
perform PCI in patients with stable angina de-
spite a lack of evidence that PCI is superior to 
guideline-directed medical therapy. Data are lack-
ing from trials comparing PCI plus guideline-
directed medical therapy with guideline-directed 
medical therapy alone in patients with stable 
coronary artery disease to show a survival benefit 
associated with PCI.1 Even the role of PCI in 
symptom relief has been questioned, as shown 
in the ORBITA (Objective Randomised Blinded 
Investigation with Optimal Medical Therapy of 
Angioplasty in Stable Angina) trial.2
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Guidelines recommend PCI for patients with 
angina that causes unacceptable symptoms de-
spite the use of medical therapy.3,4 These guide-
lines are often not followed in clinical practice. 
One study showed that approximately half of all 
PCI procedures could not be classified as appro-
priate, often because the patients had not re-
ceived an adequate course of medical therapy.5 
Imagine the outcry from regulators and insurers 
if the initial approach to stable back pain was 
surgery.
Trials of therapy for patients with cardiovascu-
lar disease should evaluate all guideline-recom-
mended approaches, particularly those that do 
not involve the use of many resources and those 
with low risks. The MR-INFORM trial is no ex-
ception. PCI comes with risks. Although the 
trial showed that the use of cardiovascular mag-
netic resonance imaging (MRI) was associated 
with a lower incidence of invasive coronary angi-
ography and coronary revascularization than 
was the use of FFR, PCI is often an end point of 
both approaches. The absence of a guideline-
directed medical therapy–only cohort is a funda-
mental drawback of the MR-INFORM trial.
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To the Editor: Nagel et al. report that a non-
invasive approach with myocardial-perfusion car-
diovascular MRI was noninferior to an invasive 
approach including coronary angiography and 
FFR assessment for the evaluation of patients 
with stable angina. In our opinion, the trial is 
interesting and well conducted and adds another 
tool to the physician’s armamentarium to detect 
ischemia. At the same time, the calculation of 
the sample size may have led to nondefinitive re-
sults. The authors based their sample-size calcu-
lation on event rates from the FAME (Fractional 
Flow Reserve versus Angiography for Multivessel 
Evaluation) trial1; those rates are higher than 
event rates in the current population of patients 
with stable coronary artery disease (10% vs. ap-
proximately 5%).2 Most importantly, Nagel and 
colleagues chose a noninferiority margin of 
6 percentage points, meaning that they would 
have accepted an upper confidence bound that 
was 60% higher in the experimental group than 
the expected 10% event rate in the control group 
in order to declare noninferiority. We acknowledge 
that this statistical approach is widely used in 
noninferiority trials, but it probably reduces the 
power of the results to a hypothesis requiring 
confirmation in bigger studies.
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The authors reply: In reply to O’Rourke and 
Adji: we can confirm that FFR was measured ac-
cording to established methods.1,2 The standard 
setup in the cardiac catheter laboratory is to en-
sure that the measuring sites (guiding catheter 
for the mean aorta pressure and distal guidewire 
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for the mean distal coronary pressure) are ap-
proximately in the same position in relation to 
the right atrium. The position of the sensor of the 
diagnostic guidewire should usually be 6 to 9 cm 
from the end of the guiding catheter and 3 cm 
distal to the lesion. There may be variations ac-
cording to the specific circumstances (e.g., lesion 
location). All these factors reflect the strengths 
and limitations of measuring “lesion-level,” pres-
sure-derived estimates of flow limitation, which 
underpin the clinical evidence supporting the 
guideline recommendations for FFR-guided man-
agement in contemporary practice.3 Each of the 
diagnostic strategies involving noninvasive MRI 
or invasive angiography with FFR has merits 
and limitations.4 Our trial was designed and 
powered to assess health outcomes between the 
randomized groups, and noninferiority criteria 
were met.
Deschner and Glanz comment about a guide-
line-directed medical therapy–only group in our 
trial. All treatment options were possible, includ-
ing guideline-directed medical therapy, PCI, and 
coronary-artery bypass grafting. The composite 
primary outcome was death, nonfatal myocardial 
infarction, or target-vessel revascularization with-
in 1 year. As expected, the noninvasive strategy 
reduced the need for coronary angiography and 
associated coronary revascularization. At the out-
set of this trial, we did not know whether not 
using invasive management and revasculariza-
tion in some patients would be safe, associated 
with a need for an unplanned procedure at a 
later stage, or both. Although ISCHEMIA (the 
International Study of Comparative Health Effec-
tiveness with Medical and Invasive Approaches) 
is under way to answer the question regarding a 
strategy of guideline-directed medical therapy 
only, the majority of deaths in the MR-INFORM 
trial occurred in patients with severe ischemia.
Finally, with regard to the comments by Te-
baldi et al.: in the FAME trial, one third of the 
participants had a history of medically stabilized 
acute coronary syndrome, which may explain why 
the incidence of major adverse cardiovascular 
events was higher in the FAME trial than in the 
MR-INFORM trial. We accept that the upper 
bound of the noninferiority margin in our trial 
may be viewed as being comparatively high. 
Nonetheless, given that the percentages of pa-
tients in whom the primary outcome occurred in 
the MRI- and FFR-guided groups were 3.6% and 
3.7%, respectively, (risk difference, −0.2 percent-
age points; 95% confidence interval, −2.7 to 2.4), 
noninferiority criteria were clearly met.
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Treatment of Hypertension in Patients with Asthma
To the Editor: In their review article, Christian-
sen and Zuraw (Sept. 12 issue)1 summarize the 
current management of hypertension in patients 
with asthma. However, the article does not men-
tion the potential merits of the use of anticho-
linergic agents, which have less cardiovascular 
stimulation and interaction with drugs for hyper-
tension than β2-agonists, as alternative or add-on 
medications to β2-agonists in such patients.
Anticholinergic bronchodilators have been 
recommended for patients with asthma who 
could not receive β2-agonists or for patients with 
asthma attacks induced by beta-blockers.2,3 In 
addition, a long-acting anticholinergic broncho-
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